Targeted Genetic Sequencing Analysis of 223 Cases of Pseudomyxoma Peritonei Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Shows Survival Related to GNAS and KRAS Status

Ähnliche Einträge

• Long‐Term Survival Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy ( HIPEC ) for Pseudomyxoma Peritonei: A 22‐Year Single Institution Experience
  von: Harleen Kaur, et al.
  Veröffentlicht: (2025)
• The Emerging Role of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Pancreatic Cancer
  von: Cornelius Thiels, et al.
  Veröffentlicht: (2024)
• The Pattern, Management, and Outcomes of Recurrence Following Cytoreductive Surgery for Pseudomyxoma Peritonei
  von: Rennie Xinrui Qin, et al.
  Veröffentlicht: (2025)
• Multisocietal Consensus on the use of Cytoreductive Surgery and HIPEC for the Treatment of Pseudomyxoma Peritonei: A GRADE Approach for Evidence Evaluation and Recommendation
  von: Shigeki Kusamura, et al.
  Veröffentlicht: (2025)
• The use of ROTEM in Detection of Coagulopathy and Altered Hemostasis in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
  von: Abdullah Mashat, et al.
  Veröffentlicht: (2025)